REPORT ID 5068

United States Dermatomyositis Drug Market Report 2017

Publish Date
20-Dec-17
Pages
114
Format
Electronic (PDF)

In this report, the United States Dermatomyositis Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Dermatomyositis Drug in these regions, from 2012 to 2022 (forecast).

United States Dermatomyositis Drug market competition by top manufacturers/players, with Dermatomyositis Drug sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    MedImmune LLC
    Neovacs SA
    Novartis AG
    Octapharma AG
    Pfizer Inc
    Eli Lilly and Company
    F. Hoffmann-La Roche Ltd
    Hope Pharmaceuticals Inc
    Idera Pharmaceuticals Inc
    KPI Therapeutics Inc
    Marathon Pharmaceuticals LLC

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Abatacept
    Baricitinib
    Dalazatide
    Immune Globulin
    IMO-8400
    Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Clinic
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Dermatomyositis Drug Market Report 2017
1 Dermatomyositis Drug Overview
    1.1 Product Overview and Scope of Dermatomyositis Drug
    1.2 Classification of Dermatomyositis Drug by Product Category
        1.2.1 United States Dermatomyositis Drug Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Dermatomyositis Drug Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 Abatacept
        1.2.4 Baricitinib
        1.2.5 Dalazatide
        1.2.6 Immune Globulin
        1.2.7 IMO-8400
        1.2.8 Others
    1.3 United States Dermatomyositis Drug Market by Application/End Users
        1.3.1 United States Dermatomyositis Drug Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Others
    1.4 United States Dermatomyositis Drug Market by Region
        1.4.1 United States Dermatomyositis Drug Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Dermatomyositis Drug Status and Prospect (2012-2022)
        1.4.3 Southwest Dermatomyositis Drug Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Dermatomyositis Drug Status and Prospect (2012-2022)
        1.4.5 New England Dermatomyositis Drug Status and Prospect (2012-2022)
        1.4.6 The South Dermatomyositis Drug Status and Prospect (2012-2022)
        1.4.7 The Midwest Dermatomyositis Drug Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Dermatomyositis Drug (2012-2022)
        1.5.1 United States Dermatomyositis Drug Sales and Growth Rate (2012-2022)
        1.5.2 United States Dermatomyositis Drug Revenue and Growth Rate (2012-2022)

2 United States Dermatomyositis Drug Market Competition by Players/Suppliers
    2.1 United States Dermatomyositis Drug Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Dermatomyositis Drug Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Dermatomyositis Drug Average Price by Players/Suppliers (2012-2017)
    2.4 United States Dermatomyositis Drug Market Competitive Situation and Trends
        2.4.1 United States Dermatomyositis Drug Market Concentration Rate
        2.4.2 United States Dermatomyositis Drug Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Dermatomyositis Drug Manufacturing Base Distribution, Sales Area, Product Type

3 United States Dermatomyositis Drug Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Dermatomyositis Drug Sales and Market Share by Region (2012-2017)
    3.2 United States Dermatomyositis Drug Revenue and Market Share by Region (2012-2017)
    3.3 United States Dermatomyositis Drug Price by Region (2012-2017)

4 United States Dermatomyositis Drug Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Dermatomyositis Drug Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Dermatomyositis Drug Revenue and Market Share by Type (2012-2017)
    4.3 United States Dermatomyositis Drug Price by Type (2012-2017)
    4.4 United States Dermatomyositis Drug Sales Growth Rate by Type (2012-2017)

5 United States Dermatomyositis Drug Sales (Volume) by Application (2012-2017)
    5.1 United States Dermatomyositis Drug Sales and Market Share by Application (2012-2017)
    5.2 United States Dermatomyositis Drug Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Dermatomyositis Drug Players/Suppliers Profiles and Sales Data
    6.1 MedImmune LLC
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Dermatomyositis Drug Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 MedImmune LLC Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Neovacs SA
        6.2.2 Dermatomyositis Drug Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Neovacs SA Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Novartis AG
        6.3.2 Dermatomyositis Drug Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Novartis AG Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Octapharma AG
        6.4.2 Dermatomyositis Drug Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Octapharma AG Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Pfizer Inc
        6.5.2 Dermatomyositis Drug Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Pfizer Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Eli Lilly and Company
        6.6.2 Dermatomyositis Drug Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Eli Lilly and Company Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 F. Hoffmann-La Roche Ltd
        6.7.2 Dermatomyositis Drug Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Hope Pharmaceuticals Inc
        6.8.2 Dermatomyositis Drug Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Hope Pharmaceuticals Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Idera Pharmaceuticals Inc
        6.9.2 Dermatomyositis Drug Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Idera Pharmaceuticals Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 KPI Therapeutics Inc
        6.10.2 Dermatomyositis Drug Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 KPI Therapeutics Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Marathon Pharmaceuticals LLC

7 Dermatomyositis Drug Manufacturing Cost Analysis
    7.1 Dermatomyositis Drug Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Dermatomyositis Drug

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Dermatomyositis Drug Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Dermatomyositis Drug Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Dermatomyositis Drug Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Dermatomyositis Drug Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Dermatomyositis Drug Sales Volume Forecast by Type (2017-2022)
    11.3 United States Dermatomyositis Drug Sales Volume Forecast by Application (2017-2022)
    11.4 United States Dermatomyositis Drug Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer